Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Pharma Says USPTO Upholds Key Antisense Patents

Premium

Santaris Pharma announced this week that the US Patent and Trademark Office has upheld the patentability of two of its antisense technology patents, which had been under re-examination at the request of Isis Pharmaceuticals.

Specifically, the USPTO revoked the re-exam of US patent No. 6,268,490, entitled “Bicyclonucleoside and Oligonucleotide Analogues,” and issued an action closing prosecution of the re-examination of US patent No. 6,770,748, also entitled “Bicyclonucleoside and Oligonucleotide Analogues,” Santaris said. Both patents relate to
locked nucleic acid or bicyclic nucleic acid chemical structures used to develop antisense molecules.

"The positive USPTO rulings are very important as the ... patents are one of the cornerstones of Santaris [Pharma's] significant patent estate, which broadly covers the 2'-4' bicyclic nucleotide universe,” Santaris CSO Henrik Orum said in a statement.

The USPTO rulings come on the heels of a patent-infringement lawsuit Isis filed against in September (GSN 9/29/2011). In that litigation, Isis claims that Santaris is infringing its intellectual property by providing antisense drugs and drug-discovery services to pharmaceutical partners.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.